Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Ozols, Robert F.; Bundy, Brian N.; Greer, Benjamin E.; Fowler, Jeffrey M.; Clarke‐Pearson, Daniel L.; Burger, Robert A.; Mannel, Robert S.; DeGeest, Koen; Hartenbach, Ellen M.; Baergen, Rebecca N.

doi:10.1200/jco.2003.02.153

Cited by 1,864 publications

(1,208 citation statements)

References 19 publications

Supporting

Mentioning

1,158

Contrasting

Unclassified

Order By: Relevance

“…It is now well established that first-line treatment should include a platinum compound (Harries and Gore, 2002), with carboplatin being the drug of choice, having been shown to have equivalent efficacy but less toxicity than cisplatin (Alberts, 1995;Du Bois et al, 1999;Ozols et al, 2003). Two large randomised studies in the 1990s of first-line therapy for ovarian cancer showed a survival benefit when a paclitaxel -platinum combination was compared with the previous standard of cyclophosphamidecisplatin; therefore, the combination of platinum and paclitaxel became standard first-line therapy (McGuire et al, 1996;Piccart et al, 2000).…”

mentioning

confidence: 99%

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

et al. 2004

View full text Add to dashboard Cite

A total of 53 women with chemotherapy-naïve stage Ic-IV ovarian cancer were treated with four cycles of carboplatin area under the curve 7 every 3 weeks, followed by four cycles of paclitaxel 70 mg m À2 (days 1, 8, and 15) and gemcitabine 1000 mg m À2 (days 1 and 8) every 3 weeks. In all, 37 (70%) had stage III/IV disease, with 22 (42%) having tumour 42 cm; 38 patients (72%) completed all planned treatment; 27 of the 32 (84%) patients with radiologically evaluable disease had partial or complete responses; and 30 of the 39 patients (77%) with elevated cancer antigen (CA) 125 had a greater than 75% fall in this value. At a median follow-up of 28 months, 31 patients had relapsed with a median progression-free survival of 19.5 months. In total, 79% of patients were alive at 2 years. Common Toxicity Criteria grade 3/4 haematological toxicity, predominantly neutropenia, was seen in 57% of the patients. A certain degree of pulmonary toxicity was observed; eight patients had symptomatic breathlessness, 7 decreased diffusing capacity of the lung for carbon monoxide, and interstitial chest X-ray changes during the weekly phase. In all cases, this toxicity was reversible. No significant neurotoxicity was seen. This regimen is generally well tolerated with encouraging efficacy. However, the observation of pulmonary toxicity, potentially a feature of the weekly taxane -gemcitabine regimen, was of some concern. Alternative schedules, including 3-weekly taxanes, are currently being evaluated.

show abstract

mentioning

confidence: 99%

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

“…When looking at survival by subgroup, IP therapy was found to be beneficial both for patients with visible disease (about 2/3 of patients) and for patients with microscopic disease, with overall survival relative risk of 0.77 and 0.69, respectively. When looking at negative second look rates in GOG-172 and other GOG studies in optimal ovarian cancer (GOG-104, GOG-158 [24], and GOG-172), the negative second look rate in the IP arm in GOG-104 was 47% as compared to the 57% negative second look rare in the IP arm of GOG-172. The intravenous treatment groups from these studies showed a 36% negative second look rate in GOG-104, 46% in GOG-158, and a comparable 41% in GOG-172.…”

Section: Gog-172mentioning

confidence: 93%

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

Alberts

Markman²,

Fm³

et al. 2006

Gynecologic Oncology

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S. The concept of intraperitoneal drug delivery for therapy of intraperitoneal cancers, such as ovarian cancer, arose in the 1960s. The field of intraperitoneal cisplatin therapy for ovarian cancer was initiated in the late 1970s and early 1980s. The markedly improved survival data resulting from a third phase III trial of intraperitoneal cisplatin for ovarian cancer in early 2006 led to an NCI Clinical Announcement and a Gynecologic Oncology Group-sponsored workshop on Intraperitoneal Therapy in January, 2006, in San Diego, California. The proceedings of this workshop summarize both research trial results and practical implementation issues associated with intraperitoneal therapy discussed at this workshop.

show abstract

“…The accepted standard is 6 cycles of platinum-based combination chemotherapy, with a platinum (carboplatin or cisplatin) and a taxane (paclitaxel or docetaxel) [52][53][54][55][56]. Docetaxel may be considered in selected patients as it has less neurotoxicity, but it is more myelosuppressive than paclitaxel [52].…”

Section: Chemotherapy For Advanced Stage Ovarian Cancermentioning

confidence: 99%

Cancer of the ovary, fallopian tube, and peritoneum

Berek

Crum

Friedlander

2015

Intl J Gynecology & Obste

121

119

View full text Add to dashboard Cite

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Abstract: In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin plus paclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus paclitaxel.

Cited by 1,864 publications

References 19 publications

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

Cancer of the ovary, fallopian tube, and peritoneum

Contact Info

Product

Resources

About